Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC) at an advanced stage (stage IIIB or IV), confirmed by laboratory testing, and whose cancer has specific genetic markers known as ALK-positive or ROS1-positive
- People who are currently being treated with a medication called lorlatinib as part of their standard cancer treatment
- People who have experienced documented thinking or memory-related side effects that are linked to taking lorlatinib
- People who are 18 years of age or older
- People whose general physical functioning falls within an acceptable range as assessed by their doctor (confirm with trial site)
- People who are able to understand and sign a consent form agreeing to take part in the trial
- People whose doctors expect them to live for at least 6 months
- People for whom their treating doctor has already planned to start a medication called vortioxetine as part of their standard care
- People who are able to complete memory and thinking tests and questionnaires written in Spanish
Who may not be able to join:
- People who had significant memory or thinking problems before their cancer treatment began
- People who are currently taking another antidepressant medication that cannot be safely stopped
- People who have a major mental health condition that is not currently under control
- People who have a history of epilepsy that is not well controlled, or who have had seizures recently
- People who have serious liver or kidney problems
- People who are known to have had an allergic reaction to vortioxetine
- People who have taken part in another clinical trial within the past 30 days
- People who are not able to give informed consent to participate
- People whose doctors estimate they have less than 3 months to live
- People for whom vortioxetine is medically unsuitable — for example, people taking a type of medication called MAOIs at the same time
- People who have previously taken vortioxetine
- People who have serious mental health conditions or significant thinking and memory difficulties that are not related to lorlatinib
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +57 310 8593083
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Psychomotor Speed; Processing Speed and Visual Attention; Executive Function and Cognitive Flexibility; Selective and Sustained Attention; Working Memory; Processing Speed; Verbal Learning and Memory; Language; Language; Frontal Lobe and Executive Function; Subjective Cognitive Complaints; Subjective Cognitive Complaints; Clinical Global Impression of Improvement (CGI-I)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.